MaxCyte signs strategic platform license with Vertex Pharmaceuticals

MaxCyte Inc MXCT has signed a strategic platform license with Vertex Pharmaceuticals Incorporated VRTX.

The MaxCyte technology was used in the development of exa-cel under an agreement between MaxCyte and CRISPR Therapeutics AG Price Action. MXCT shares are up 10.2% at $6.40 on the last check Wednesday.

Benzinga does not provide investment advice.